Angiogenic hydrogels for dental pulp revascularization

Siddiqui, Zain; Sarkar, Biplab; Kim, Ka Kyung; Kadincesme, Nurten; Paul, Reshma; Kumar, Arjun; Kobayashi, Yoshifumi; Roy, Abhishek; Choudhury, Minati; Yang, Jian; Shimizu, Emi; Kumar, Vivek

doi:10.1016/j.actbio.2021.03.001

Cited by 49 publications

(63 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While holding significant progress, peptide therapeutics still suffer from key limitations associated with: stability (API and formulation [ 99 , 186 , 187 , 188 , 189 ] /in vitro and in vivo [ 190 , 191 , 192 , 193 , 194 ] ); susceptibility to proteases [ 190 , 195 , 196 , 197 , 198 , 199 , 200 ] potential immune (IgG) responses [ 120 , 201 , 202 , 203 ] cost at scale [ 204 , 205 , 206 , 207 ] pharmacokinetic bioavailability. [ 208 , 209 , 210 , 211 , 212 ] Notwithstanding, numerous strategies have been explored to overcome these challenges and others, including self‐assembling peptides from our group [ 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 ] and others. [ 221 , 222 , 223 , 224 , 225 ]…”

Section: Discussionmentioning

confidence: 99%

Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV

Panchal

Kataria

Patel

et al. 2021

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

The COVID‐19 (coronavirus disease) global pandemic, caused by the spread of the SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) virus, currently has limited treatment options which include vaccines, anti‐virals, and repurposed therapeutics. With their high specificity, tunability, and biocompatibility, small molecules like peptides are positioned to act as key players in combating SARS‐CoV‐2, and can be readily modified to match viral mutation rate. A recent expansion of the understanding of the viral structure and entry mechanisms has led to the proliferation of therapeutic viral entry inhibitors. In this comprehensive review, inhibitors of SARS and SARS‐CoV‐2 are investigated and discussed based on therapeutic design, inhibitory mechanistic approaches, and common targets. Peptide therapeutics are highlighted, which have demonstrated in vitro or in vivo efficacy, discuss advantages of peptide therapeutics, and common strategies in identifying targets for viral inhibition.

show abstract

Section: Discussionmentioning

confidence: 99%

Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV

Panchal

Kataria

Patel

et al. 2021

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, angiogenic hydrogels have similar material properties to that of the native dental pulp and can promote ideal biointegration and soft tissue regeneration. They have been shown to re-establish vasculature in dental root canals [150].…”

Section: Regenerative Endodonticsmentioning

confidence: 99%

Polymeric Scaffolds for Dental, Oral, and Craniofacial Regenerative Medicine

Munguia-Lopez

Cho

et al. 2021

Molecules

View full text Add to dashboard Cite

Dental, oral, and craniofacial (DOC) regenerative medicine aims to repair or regenerate DOC tissues including teeth, dental pulp, periodontal tissues, salivary gland, temporomandibular joint (TMJ), hard (bone, cartilage), and soft (muscle, nerve, skin) tissues of the craniofacial complex. Polymeric materials have a broad range of applications in biomedical engineering and regenerative medicine functioning as tissue engineering scaffolds, carriers for cell-based therapies, and biomedical devices for delivery of drugs and biologics. The focus of this review is to discuss the properties and clinical indications of polymeric scaffold materials and extracellular matrix technologies for DOC regenerative medicine. More specifically, this review outlines the key properties, advantages and drawbacks of natural polymers including alginate, cellulose, chitosan, silk, collagen, gelatin, fibrin, laminin, decellularized extracellular matrix, and hyaluronic acid, as well as synthetic polymers including polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), poly (ethylene glycol) (PEG), and Zwitterionic polymers. This review highlights key clinical applications of polymeric scaffolding materials to repair and/or regenerate various DOC tissues. Particularly, polymeric materials used in clinical procedures are discussed including alveolar ridge preservation, vertical and horizontal ridge augmentation, maxillary sinus augmentation, TMJ reconstruction, periodontal regeneration, periodontal/peri-implant plastic surgery, regenerative endodontics. In addition, polymeric scaffolds application in whole tooth and salivary gland regeneration are discussed.

show abstract

“…Subsequent addition of charged ions, drugs or other polymers facilitates terminal charge shielding in these domains and allows for unidirectional fiber extension as well as three-dimensional intertangling of multiple fibers, ultimately giving rise to stiff, optically clear, thixotropic hydrogels [ 23 , 27 , 32 , 33 , 34 , 35 , 36 ]. While this base sequence has shown excellent promise as a scaffold for wound healing, drug delivery and tissue regeneration [ 24 , 26 , 27 , 28 , 32 , 35 , 36 , 37 , 38 ], additional functionality can be incorporated by appending short epitopes at one of the termini, generating new A-B-A-C-type hydrogels which can be used to promote neurogenesis or dentinogenesis, modulate inflammation, reduce bacterial load or regulate lipoprotein homeostasis [ 39 , 40 , 41 , 42 , 43 , 44 ]. Of these designer hydrogels, versions which are either pro- or anti-angiogenic have recently shown great potential for tissue regeneration in several disparate biomedical applications [ 40 , 43 , 45 , 46 , 47 , 48 , 49 , 50 ].…”

Section: Introductionmentioning

confidence: 99%

“…While this base sequence has shown excellent promise as a scaffold for wound healing, drug delivery and tissue regeneration [ 24 , 26 , 27 , 28 , 32 , 35 , 36 , 37 , 38 ], additional functionality can be incorporated by appending short epitopes at one of the termini, generating new A-B-A-C-type hydrogels which can be used to promote neurogenesis or dentinogenesis, modulate inflammation, reduce bacterial load or regulate lipoprotein homeostasis [ 39 , 40 , 41 , 42 , 43 , 44 ]. Of these designer hydrogels, versions which are either pro- or anti-angiogenic have recently shown great potential for tissue regeneration in several disparate biomedical applications [ 40 , 43 , 45 , 46 , 47 , 48 , 49 , 50 ].…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we investigated the preclinical efficacy of two novel peptide hydrogels, one containing a pro-angiogenic [ 43 ] motif and the other an anti-angiogenic motif in a rat wet AMD model ( Figure 1 ) [ 6 ]. Both novel peptide hydrogels demonstrate biocompatibility, targeted delivery, sustained release, and optical clarity—important design criteria for biomaterials for wet AMD treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to Treat Age-Related Macular Degeneration

et al. 2021

Self Cite

View full text Add to dashboard Cite

Pro-angiogenic and anti-angiogenic peptide hydrogels were evaluated against the standard of care wet age-related macular degeneration (AMD) therapy, Aflibercept (Eylea®). AMD was modeled in rats (laser-induced choroidal neovascularization (CNV) model), where the contralateral eye served as the control. After administration of therapeutics, vasculature was monitored for 14 days to evaluate leakiness. Rats were treated with either a low or high concentration of anti-angiogenic peptide hydrogel (0.02 wt% 8 rats, 0.2 wt% 6 rats), or a pro-angiogenic peptide hydrogel (1.0 wt% 7 rats). As controls, six rats were treated with commercially available Aflibercept and six with sucrose solution (vehicle control). Post lasering, efficacy was determined over 14 days via fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT). Before and after treatment, the average areas of vascular leak per lesion were evaluated as well as the overall vessel leakiness. Unexpectedly, treatment with pro-angiogenic peptide hydrogel showed significant, immediate improvement in reducing vascular leak; in the short term, the pro-angiogenic peptide performed better than anti-angiogenic peptide hydrogel and was comparable to Aflibercept. After 14 days, both the pro-angiogenic and anti-angiogenic peptide hydrogels show a trend of improvement, comparable to Aflibercept. Based on our results, both anti-angiogenic and pro-angiogenic peptide hydrogels may prove good therapeutics in the future to treat wet AMD over a longer-term treatment period.

show abstract

Angiogenic hydrogels for dental pulp revascularization

Cited by 49 publications

References 74 publications

Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV

Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV

Polymeric Scaffolds for Dental, Oral, and Craniofacial Regenerative Medicine

Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to Treat Age-Related Macular Degeneration

Contact Info

Product

Resources

About